Core Viewpoint - Green Leaf Pharmaceutical (02186) experienced a stock price increase of over 5% following the release of its interim results, with the current price at HKD 3.53 and a trading volume of HKD 180 million [1] Financial Performance - For the six months ending June 30, 2025, the company reported a revenue of RMB 3.181 billion, representing a year-on-year increase of 3.46% [1] - The profit attributable to the parent company was RMB 313 million, a decrease of 19.33% year-on-year [1] - Earnings per share stood at 8.32 cents [1] Segment Performance - Revenue from the oncology treatment segment increased by 13.5%, reaching RMB 1.295 billion [1] - Revenue from the central nervous system treatment segment grew by 5.4%, amounting to RMB 868 million [1] - Revenue from the cardiovascular treatment segment decreased by 9.2%, totaling RMB 693 million [1] - Revenue from the metabolic treatment segment declined by 7.9%, reaching RMB 180 million [1]